Načítá se...
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
BACKGROUND: The bisdioxopiperazine dexrazoxane (DRZ) prevents anthracycline-induced heart failure, but its clinical use is limited by uncertain cardioprotective mechanism and by concerns of interference with cancer response to anthracyclines and of long-term safety. METHODS: We investigated the effe...
Uloženo v:
| Vydáno v: | BMC Cancer |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4242484/ https://ncbi.nlm.nih.gov/pubmed/25406834 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-842 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|